Zoeken

PRO een koppeling hebt gedeeld

2024-08-08 13:10:03 ·

The latest report by Precision Business Insights, titled #proteomic #biomarker #analytics market covers complete information on market size, share, growth, trends, segment analysis, key players, drivers, and restraints.

https://www.precisionbusinessinsights.com/market-reports/proteomic-biomarker-analytics-market

The latest report by Precision Business Insights, titled #proteomic #biomarker #analytics market covers complete information on market size, share, growth, trends, segment analysis, key players, drivers, and restraints. https://www.precisionbusinessinsights.com/market-reports/proteomic-biomarker-analytics-market

WWW.PRECISIONBUSINESSINSIGHTS.COM

Proteomic Biomarker Analytics Market Size, Growth Insights 2030

·383 Views ·0 voorbeeld

PRO een koppeling hebt gedeeld

2024-06-20 11:28:18 ·

The report "Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV), By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes, Others) - Global Forecasts to 2030"

The global prostate cancer diagnostic market is projected to reach USD 126.5 billion in 2023, registering a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period 2024-2030. The growth of the market is majorly driven by the innovation in drugs and developments in genomics and proteomics

Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=22416

Competitive Dashboard:
The prominent key players operating in the global prostate cancer diagnostic market are Accuquik Test Kits (U.S.), ACON Laboratories, Inc. (U.S.), bioMérieux SA (France), HUMASIS (South Korea), Teco Diagnostics (U.S.), Hologic Inc. (U.S.), MDxHealthcare (Belgium), Abbott (U.S.), Siemens Healthcare GmbH (Germany), OPKO Health Inc. (U.S.), Myriad Genetics, Inc. (U.S.), DiaSorin S.p.A (Italy), Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.), Metamark Genetics, Inc. (U.S.), Prostatype Genomics (Switzerland), Fujirebio (Belgium), Proteomedix (Switzerland), Eurolyser Diagnostica GmbH (Austria), F. Hoffmann-La Roche Ltd (Switzerland)

The report "Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV), By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes, Others) - Global Forecasts to 2030" The global prostate cancer diagnostic market is projected to reach USD 126.5 billion in 2023, registering a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period 2024-2030. The growth of the market is majorly driven by the innovation in drugs and developments in genomics and proteomics Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=22416 Competitive Dashboard: The prominent key players operating in the global prostate cancer diagnostic market are Accuquik Test Kits (U.S.), ACON Laboratories, Inc. (U.S.), bioMérieux SA (France), HUMASIS (South Korea), Teco Diagnostics (U.S.), Hologic Inc. (U.S.), MDxHealthcare (Belgium), Abbott (U.S.), Siemens Healthcare GmbH (Germany), OPKO Health Inc. (U.S.), Myriad Genetics, Inc. (U.S.), DiaSorin S.p.A (Italy), Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.), Metamark Genetics, Inc. (U.S.), Prostatype Genomics (Switzerland), Fujirebio (Belgium), Proteomedix (Switzerland), Eurolyser Diagnostica GmbH (Austria), F. Hoffmann-La Roche Ltd (Switzerland)

WWW.PRECISIONBUSINESSINSIGHTS.COM

Request Sample

·1K Views ·0 voorbeeld

Registreer

Talen

Proteomic Biomarker Analytics Market Size, Growth Insights 2030

Request Sample